Clinical TrialsSearch results
Number of results: 341
Recruiting
- Utility of Antigen Detecting Tests of Serum and BALF in Diagnosing Respiratory Infectious Diseases
- Respiratory Infectious Diseases
- Nagasaki University Graduate School of Biomedical Sciences
- 2009-11-09
Other
- a phase II trial of amrubicin and carboplatin for patients with extensive stage small cell lung cancer
- small cell lung cancer
- Nagasaki Thoracic Oncology Group
- 2008-04-09
Other
- Evaluation of the steroid ointment utility to prevent the injection site reactions and phlebitis caused by vinorelbine.
- cancer
- Nagasaki Thoracic Oncology Group
- 2012-12-31
Other
- phase II study of Erlotinib for non-small cell lung cancer patients with EGFR mutation
- non-small cell lung cancer
- Nagasaki Thoracic Oncology Group
- 2009-04-04
Other
- Phase II study of TS-1 for patients with advanced non-small cell lung cancer treated with prior chemotherapy.
- Non-small cell lung cancer
- Nagasaki Thoracic Oncology Group
- 2007-09-05
Other
- Phase II study of TS-1 in elderly patients with unresectable non-small cell lung cancer
- Non-small cell lung cancer
- Nagasaki Thoracic Oncology Group
- 2007-08-11
Other
- Relationship between the response to CPT-11/platimun regimen and BCRP DNA Metylation in patients with NSCLC recurrence after surgical resection.
- NSCLC
- Nagasaki Thoracic Oncology Group
- 2012-12-31
Other
- To evaluate the relationships between the serum concentration of EGFR-TKIs and the effects and toxicities of them
- NSCLC
- Nagasaki Thoracic Oncology Group
- 2013-12-31
Other
- A Switch Therapy for Community-acquired Pneumonia: A Randomized Controlled Trial
- Community-acquired pneumonia in adults
- Nagasaki evaluation organization for clinical interventions
- 2009-07-01
Other
- Comparative Study of Usefulness of TAZ/PIPC and MEPM in Healthcare Associated Pneumonia (HCAP): Survey on the Actual Condition of Healthcare Associated Pneumonia (HCAP) in Japan
- Healthcare associated pneumonia (HCAP) with a pneumonia severity index (PSI) score in risk class III or IV
- Nagasaki evaluation organization for clinical interventions
- 2009-08-01